RESULTS
Table 1 summarizes demographics of 321 unique childhood cancer survivors seen during this interval; 227 (70.7%) in-person and 94 (29.3%) via telehealth. Survivors were 1 - 18.6-years (median 6.9 years) after completion of all cytotoxic therapies. Most common diagnoses included leukemia/lymphoma (28.4%, n=91), neuroblastoma (19%, n=61), and non-malignant hematologic disorders (12.5%, n=40). Ninety-nine patients (30.9%) had history of prior HCT. Thirty-five patients (10.9%) reported prior symptoms consistent with COVID-19 infection. SARS-CoV-2 serology results in the context of reported symptoms and known COVID-19 exposures are summarized in Table 2 . Six patients (1.9%) experienced family member deaths due to COVID-19, including grandparents (n=5) and one aunt.
Among 257 (80.1%) patients who had SARS-CoV-2 IgG testing, 20 (7.8%) patients had positive antibodies [Table 1 ]. Most common diagnoses among patients with positive serology included leukemia/lymphoma (25%, n=5), non-malignant hematologic disorders (25%, n=5), and sarcoma (15%, n=3). One-half of patients with positive SARS-CoV-2 IgG resided in two zip codes located in Kings County, Brooklyn (30%, n=6) and the Bronx (20%, n=4). Of all patients seen, these residencies were reported by 14.6% (n=47) and 3.7% (n=12), respectively. Among patients with positive SARS-CoV-2 serology, 35% (n=7) were HCT survivors.
Five (1.6%) patients reported history of PCR-confirmed SARS-CoV-2 infection. Four of 5 patients had COVID-19 antibodies drawn at their visits, and all had positive seroconversion between 2 to 5 months after reported infection (100%). Among these patients, 2 had never developed symptoms; 2 had mild symptoms including fever (n=1), headache (n=1), and loss of sense of smell (n=2); and 1 (0.3%) required hospitalization for respiratory insufficiency and myocarditis with subsequent full recovery. None of our patients developed multisystem inflammatory syndrome in children (MIS-C).